Legend Biotech Corporation (LEGN)

Nasdaq: LEGN · Pharmaceutical Preparations · Somerset, NJ · filing with the SEC since 2020

Full chart Alerts Compare

Grade6.1

◀ Past 6.9● Present 5.7▶ Future 5.8

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Legend Biotech Corporation

Nine metrics read from its own filings, by tense

Headline grade

6.1/10

◀ Past6.930% of the headline

● Present5.740% of the headline

▶ Future5.830% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2020.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Legend Biotech Corporation's filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.8/10

What has it actually done, year after year?

+54.4% a year over 8 filed years; profitable in 0 of 8.

weight 45% of this tense · 58th percentile among 323 sector filers · read for its customers

From the record

Legend Biotech Corporation's 8 filed years say what it did: revenue went from $49 million in fiscal 2018 to $1.0 billion in fiscal 2025, up 54.4% a year; it rose in 5 of 7 years; the deepest fall was 33% from fiscal 2020 to fiscal 2022; net income was positive in 0 of 8 of those years (its annual reports).

What it rests on

revenue growth over the filed span54.4%top 23% of its family
the share of years revenue rosetop 34% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak32.9%top 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

7.4/10

How has it treated the people who own it?

SI estimate 7.4/10, confidence 35 of 100 (one part).

weight 22% of this tense · 74th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 26% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Legend Biotech Corporation's shareholder treatment is put at 7.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 26% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.7/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

6.5/10

Is it financially healthy right now?

ROE -30%: lost 30¢ per shareholder dollar. Leverage 42%: owes 42¢ per asset dollar.

weight 45% of this tense · 65th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Legend Biotech Corporation lost about 30 cents for every dollar of shareholders' money, and gross profitability: its products earned about 36 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 42 cents per dollar of assets, and net share issuance: its share count grew 0.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 41% of its family
return on equitytop 34% of its family
gross profit against assetstop 33% of its family
the share count against the year beforetop 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

8.2/10

How strong is its position in its industry?

top 18% of 315 in its family; net margin -28.8%.

weight 33% of this tense · 82nd percentile among 315 sector filers · read for its customers

From the record

Legend Biotech Corporation's standing among 315 graded names in its industry family: revenue of $1.0 billion in fiscal 2025 ranks in the top 12% by size; a net margin of -28.8% ranks in the top 35%; revenue growth of 173.4% a year over the last 3 filed years ranks in the top 8% (its annual reports).

What it rests on

revenue against the family$1.03Btop 12% of its family
net margin-28.8%top 35% of its family
three-year revenue growth173.4%top 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

0.1/10

What are the people in charge doing?

SI estimate 0.1/10, confidence 35 of 100 (one part).

weight 22% of this tense · 1st percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the chief executive's years under the title, which ranks in the bottom 1% of 415 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: the chief executive's years on the record, the one part on file, ranked among 415 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Legend Biotech Corporation's leadership is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 1% of 415 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.8/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.0/10

How much room does it have to grow?

bottom 50% of 273 in its family for room to expand.

weight 45% of this tense · 50th percentile among 273 sector filers · read for itself

From the record

Legend Biotech Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $902 million against debt of $319 million leaves 33.6% of its assets as net cash, top 44% of its family; cash from operations less capital spending is -12.5% of revenue (top 34%); a gross margin of 61.4% (bottom 39%); research spending of 40.3% of revenue (bottom 38%) (its annual report).

What it rests on

cash less debt against assets33.6%top 44% of its family
cash from operations less capital spending against revenue-12.5%top 34% of its family
gross margin61.4%bottom 39% of its family
research spending against revenue40.3%bottom 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.5/10

What could actually drive growth from here?

top 25% of 306 in its family for growth drivers.

weight 33% of this tense · 75th percentile among 306 sector filers · read for its customers

From the record

Legend Biotech Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 173.4% a year over the last three filed years against 54.4% over all 8, speeding up (top 5% of its family); the newest year grew 64.1% (top 22%); research spending grew 7.3% a year (top 43%); capital spending grew 11% a year (top 30%) (its annual reports). Legend Biotech Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+119.0 points a yeartop 5% of its family
the newest year's revenue growth64.1%top 22% of its family
three-year growth of research spending7.3%top 43% of its family
three-year growth of capital spending11.0%top 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

4.9/10

Did its newest year beat what its own record pointed to?

bottom 49% of 233 in its family for expectations against reality.

weight 22% of this tense · 49th percentile among 233 sector filers · read for its shareholders

From the record

Legend Biotech Corporation's newest year against its own record: revenue of $1.0 billion in fiscal 2025 came in 53.5% below the $2.2 billion its prior three years' pace pointed to (bottom 17% of its family); net income of $297 million against a prior three-year average of $381 million (top 47%); a net margin of -28.8% against losses larger than its revenue before (top 23%) (its annual reports).

What it rests on

revenue against the prior three years' pace-53.5%bottom 17% of its family
net income against the prior three years' average+22%top 47% of its family
net margin against its prior averageup more than 100 pointstop 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton LEGN · research, not advice